MedPath

Efficacy of Nitrous Oxide in OCD: Pilot Study

Phase 2
Recruiting
Conditions
Obsessive-Compulsive Disorder
Interventions
Registration Number
NCT03826693
Lead Sponsor
Stanford University
Brief Summary

This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.

Detailed Description

Obsessive-compulsive disorder (OCD) is a chronic and disabling disorder characterized by recurrent intrusive thoughts and associated compulsive behaviors that is estimated to affect more than 3 million individuals in the US each year.

This study seeks to explore whether a single inhalation of nitrous oxide gas may bring about rapid symptom relief in OCD.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Age 18-65
  • Primary diagnosis of OCD
  • Sufficient severity of OCD symptoms
  • Ability to tolerate a treatment-free period
  • Capacity to provide informed consent
Exclusion Criteria
  • Psychiatric or medical conditions that make participation unsafe
  • Pregnant or nursing females
  • Concurrent use of any medications that might increase the risk of participation (e.g. drug interactions)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control: NitrogenNitrogenOCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
Experimental: Nitrous OxideNitrous OxideOCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
Primary Outcome Measures
NameTimeMethod
Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)1 week

Improvement in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Stanford University

🇺🇸

Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath